Washington University Physicians®

Washington University School of Medicine in St. Louis

Pathology & Immunology
Pathology Services: Molecular Oncology Services

Diagnosis-specific Algorithmic Testing
Lung

Authors: Lulu Sun, MD; Jon Ritter, MD; Fouad Boulos, MD

Purpose: To document the expectations of algorithmic test selection and approval for diagnosis-specific solid tumor testing by the Pathologists at Washington University School of Medicine.

Workflow: All orders submitted for pathology on inpatient and outpatient solid tumors are assessed for the appropriateness of testing based on correlation with new and existing clinical data. The approval process only applies to solid tumors and only to the specific testing detailed within this document. The Pathologist reviewing the pathology case will be responsible for the triaging of orders.

- Requests for algorithmic testing require that the pathology be resulted prior to ordering of any assays listed in this document. In cases where sample processing would be delayed beyond stability requirements, testing will be sent but may be canceled if later deemed inappropriate based on clinicopathologic data.
- If specific testing is required outside of the algorithmic test selection, please submit a separate order and the Pathologist will evaluate for approval.

Summary of diagnosis-specific algorithm testing for both inpatients and outpatients:
I. Lung
   a. First diagnosis, treatment naïve non-squamous, non-small cell lung carcinoma
      i. PD-L1 22c3 clone IHC
      ii. GatewaySeq
      iii. FISH for ALK, ROS, and RET
   b. First diagnosis, treatment naïve squamous cell lung carcinoma
      i. PD-L1 22c3 clone IHC
   Tempus or other outside laboratory assays will be ordered on clinician request.